Communicators

are winners!

More News

17.04.2023
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Clinical Trial of RECCE® 327
11.04.2023
New Family 4 Patent to be Granted for RECCE® Anti-Infectives
04.04.2023
Recce Receives Further A$973,144 R&D Advance
20.02.2023
Recce Pharmaceuticals Selects CMAX Research Facility for Phase I/II Urinary Tract Infection Clinical Trial
25.01.2023
RECCE - A$6.21m Received from R&D Rebate Payments
10.01.2023
Australian Patent to be Granted for RECCE® Anti-Infectives
15.12.2022
Recce Pharmaceuticals: Anti-Infective Research Unit Established at Murdoch Children’s Research Institute
09.12.2022
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study
28.10.2022
Recce Pharmaceuticals Ltd.: Quarterly Cash Flow Statement & Operational Highlights
18.10.2022
RECCE® 327 SARS-CoV-2 Study Update